Blueprint Medicines Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Blueprint Medicines (BPMC) PT Raised to $52 at Jefferies
May 4, 2017 8:24 AM EDTJefferies raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $52.00 (from $42.00) while maintaining a Buy rating.
"With add'l clinical data for 2 lead candidates (BLU-285, BLU-554) in 2017 likely to strengthen their therapeutic potential, and added clarity around approval path for... More
Blueprint Medicines (BPMC) Misses Q1 EPS by 8c
May 3, 2017 7:06 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More